Table 3.

Representative Biologic Therapies in Use or under Investigation for Eosinophilic Asthma

Target	Treatment	Studies	Patient Population	Outcomes
IL-5	Anti–IL-5 IgG mepolizumab*	Bel et al., 2014 (15); Ortega et al., 2014 (16)	Severe asthma, peripheral blood eosinophilia ≥ 150 cells/μl at screening or 300 cells/μl in the preceding year	Steroid sparing, reduced exacerbations, improved control
	Reslizumab*	Castro et al., 2015 (146)	Uncontrolled moderate to severe asthma with peripheral blood eosinophilia ≥ 400 cells/μl and ≥1 exacerbation in the past year	Reduced exacerbations
IL-5 receptor	Benralizumab	Bleecker et al., 2016 (17); FitzGerald et al., 2016 (153)	Severe asthma, peripheral blood eosinophilia > 300/μl	Reduced exacerbations, improved lung function and symptom control
IgE	Omalizumab*	Cochrane Review 2014 (154)	FDA approved for treatment of moderate to severe allergic asthma, age ≥ 6 yr	Improved asthma symptom control, reduced exacerbations, reduced eosinophil counts
IL-4 receptor, α subunit	Dupilumab	Wenzel et al., 2016 (149)	Phase IIb: Uncontrolled moderate to severe asthma (n = 769)	Improved lung function, reduced exacerbations
Prostaglandin D2 receptor 2	Fevipiprant	Gonem et al., 2016 (155)	Phase II: Moderate to severe asthma with sputum eosinophils ≥ 2%	Reduced sputum eosinophils, improved quality of life and lung function

Definition of abbreviation: FDA = U.S. Food and Drug Administration.

^*FDA approved at time of article submission.